<International Circulation>:  Dr. Brindis， what do you think stands out this year as the most outstanding feature of the ACC conference?

   《国际循环》： Brindis教授，你认为今年ACC会议的最突出的特点是什么？

    Prof. Brindis:  I haven’t had a chance to see all of the presentations but I think the highlight of this year’s meeting is the PARTNERS trial.  Here is a situation where we are looking for new avenues and new therapies for patients with severe aortic stenosis.  We appreciate， for example， that 30-40% of patients with aortic stenosis who have the net qualifications necessary from a clinical standpoint to undergo aortic valve replacement are not having that within the United States.  There could be lots of reasons.  One being poor recognition another patient refusal， and probably also physician concern with the risks of open-heart surgery with aortic valve replacement.  Looking at new therapy such as percutaneous aortic valve implantation (TAVI) allows for an increase in our armamentarium with which to treat patients with severe aortic valve stenosis.  The study has shown us that neither surgery wins nor interventional implantation wins.  The message for me of the PARTNERS trial is that decision making and team base care utilizing cardiovascular surgeons， interventional cardiologists， treating physicians， heart failure experts， and echo cardiographers all working as a team can make individual patients decisions in order to choose the best criteria and therapy.

    Brindis教授：我还没有机会看到所有的演讲，但我认为今年的会议重点是PARTNERS研究。目前我们正在为严重的主动脉瓣狭窄患者寻求新的治疗方式和方法。我们对此表示赞赏，例如，从临床角度看，在美国主动脉瓣狭窄的患者有30%～40%有必要接受主动脉瓣置换。可能有很多原因，一个是缺乏认识；另一个是病人拒绝，还有可能是医生太关注主动脉瓣置换的开胸风险。对于治疗严重主动脉瓣狭窄患者，新的治疗方式如经皮主动脉瓣植入（TAVI）增加了我们的医疗手段。这项研究已经表明，无论介入还是手术都不是赢家。PARTNERS研究给我的提示是，利用心血管外科医师、介入心脏病学专家、内科医生、心力衰竭专家以及心脏超声学专家组成一个团队来决定治疗策略和协同治疗，根据患者个体做出决定以便选择最佳的标准和治疗方案。